AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03688464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
Study NCT03688464 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
Study NCT02074839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-120
Description: AG-120 administered continuously as a single agent dosed orally every day of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression, development of other unacceptable toxicity or hematopoietic stem cell transplant.
Study NCT03330639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: Capsaicin is a homeopathic medication and there for this drug is not subject to the requirements of the FDA.
Study NCT03330639 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will receive the saline placebo solution.
Study NCT01224366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Study NCT01224366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03384641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline 200 mg
Description: Participants will receive bedaquiline 200 mg (2\*100 mg tablets) once daily for 2 weeks followed by 100 mg tablet tiw for 6 weeks with at least 48 hours between doses.
Study NCT04099329 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-game Safety Huddles
Description: Coaches will be trained to lead Pre-game Safety Huddles by the RA with the study using a multi-media tool we have developed. Huddles will be brief (1-2 minutes) and will primarily focused on 1) encouraging concussion reporting and 2) encouraging good sportsmanship
Study NCT03773146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1X Airtime Incentive
Description: An incentive given in the form of airtime
Study NCT01768195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir prophylaxis
Description: Entecavir 0.5mg daily from day 1 of immunochemotherapy and/or chemotherapy to 12 months after completing immunochemotherapy and/or chemotherapy.~In patients with low load of hepatitis B virus DNA(≤2000 IU/ml), rituximab will be administrated at the beginning of entecavir prophylaxis. And in patients with high load of hepatitis B virus DNA(>2000 IU/ml), rituximab will be administrated when hepatitis B virus DNA decreased to the level of 2000 IU/ml after entecavir prophylaxis.
Study NCT01480310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCAF5352A
Description: may receive up to 3 subcutaneous doses of MCAF5352A
Study NCT01480310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: may receive up to 3 subcutaneous doses of placebo
Study NCT03592563 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neuro-QoL questionnaire
Description: Follow-up over time will continue (either in-person or over the phone) using the same questionnaires (depending on which group they are belongs to) at approximately 6-month intervals. During each follow-up, participants will be screened for any new signs, symptoms and diagnoses of neurological and/or psychiatric disorders, in order to correlate these outcomes with risk factors captured using the procedures described above.
Study NCT03265457 — intervention group
Intervention type: OTHER
Intervention: Specular microscopy
Description: Comparison between corneal Endothelial count in patients with pseudoexfoliation syndrome and age matched group
Study NCT01575925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg Oral POM + 40 mg Oral DEX
Study NCT01575925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg Oral POM + 40 mg Oral DEX
Study NCT02945813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 850mg PO BID; 48 weeks
Study NCT02945813 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Salvage Radiotherapy SRT
Description: SRT 35 x 2Gy; 7 weeks
Study NCT02945813 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Salvage Radiotherapy SRT
Description: SRT 35 x 2Gy; 7 weeks
Study NCT03605914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac
Description: The non-steroidal anti-inflammatory drug (NSAID) used in this study is diclofenac.
Study NCT03605914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norco
Description: The opioid used in this study is Norco. Norco is a combination medication that contains both an opioid pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen).
Study NCT03773146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lottery Airtime Incentive
Description: An incentive given in the form of airtime
Study NCT02668510 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: immediately following shockwave therapy the injection of PRP derived from subjects own blood using Arthex double syringe system will be injected at the origin of the plantar fascia at the calcaneous
Study NCT02668510 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: placebo injection of normal saline immediately following shockwave therapy
Study NCT03374059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Study NCT03057275 — intervention group
Intervention type: DEVICE
Intervention: Abdominal fetal/maternal monitoring
Description: A single patch placed on the abdomen that incorporates 5 electrodes and a monitoring device
Study NCT02617654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Treatment with liraglutide for 52 weeks
Study NCT03374059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Life modification
Study NCT02617654 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for liraglutide
Description: Placebo for liraglutide. Treatment once daily for 52 weeks
Study NCT04676035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680
Description: * Experimental: Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680~* Midazolam, Warfarin, Omeprazole and VitaminK1 QD on Day 1 and Day 22, SHR3680 240 mg once daily (QD) from Study Day 6 - 27
Study NCT01714999 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bursectomy
Description: Bursectomy of the OB and PB are performed in the operation theatre under sterile conditions. In case of a laceration of the OB a leash, in case of PB a redon drainage (Charr. 10) is inserted. After application of a sterile bandage a cast is applied in both cases. Patient will receive AB for 5 days, the affected limb will be immobilized until removal of the stiches after 12-14 days.
Study NCT01714999 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bursal reconstruction
Description: The bursal laceration is treated within in ER setting. The wound is cleaned and thoroughly washed, if needed the wound margins are excised. The wound is then closed using simple suture and a plaster applied and removed 5 days later. Antibiotics are be administered for 5 days
Study NCT02416895 — intervention group
Intervention type: OTHER
Intervention: In vivo immunity model
Description: A measure of in vivo immune function.
Study NCT01195480 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: donor-derived EBV-specific cytotoxic T-cells (EBV-CTL) transduced with the retroviral vector SFGalpha-CD19-CD3zeta
Description: All patients will be treated at the same total dose level of 2 x 10\^8/m2
Study NCT01195480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Irradiated donor-derived Lymphoblastoid Cell Line
Description: The initial cohort of 5 patients (regardless of arm of study) will be treated as described. If transduced CTL infusion is safe in this initial cohort and real-time DNA PCR studies demonstrate that transduced CTL are undetectable in > 50% of patients by 2 months post-infusion, the remaining 25 patients (in either arm of the study) will be treated as above but with an additional vaccination of CD19-zeta-transduced EBV-LCL infusion.~Vaccination will consist of 3 doses of 5 x 10\^6 irradiated (70Gy) donor-derived EBV-lymphoblastoid cell line used to generate CTL and will be administered subcutaneously into the thigh (volume 0.3 ml) at day -2, week 4 and 8 post-transduced CTL infusion.
Study NCT03339440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hearts & Parks
Description: The Hearts \& Parks intervention will be looking to evaluate how different types of physical activity and nutrition education and support (in addition to normal clinical care) through attendance and participation in the Duke Healthy Lifestyles/Bull City Fit clinic/community program, affect children's health. The investigators will be looking at changes in BMI, physical activity, nutrition and overall health.
Study NCT01810497 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Use of ear bandage
Description: Elastic bandage to be used on the postoperative period of otoplasty, starting immediately after the procedure. To be used 24hours/day for the specified period.
Study NCT01678625 — intervention group
Intervention type: DEVICE
Intervention: Train-of-four ratio calculation (T4-EMG)
Description: TOF ratios will be compared between the EMG and AMG groups
Study NCT03382106 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pulse wave velocity
Description: Vascular pulse measurement at the radial, brachial, femoral, and carotid arteries are taken using a tonometer probe.
Study NCT03382106 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Pulse wave velocity
Description: Vascular pulse measurement at the radial, brachial, femoral, and carotid arteries are taken using a tonometer probe.
Study NCT03382106 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Carotid artery compliance and stiffness
Description: An echocardiogram is done by using a probe placed on the skin.
Study NCT03382106 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Carotid artery compliance and stiffness
Description: An echocardiogram is done by using a probe placed on the skin.
Study NCT03382106 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pressure wave reflection
Description: Carotid pulse measurement taken using a tonometer probe
Study NCT03382106 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Pressure wave reflection
Description: Carotid pulse measurement taken using a tonometer probe
Study NCT00414804 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Precision SCS
Description: Precision Spinal Cord Stimulation (SCS) Therapy
Study NCT00414804 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve Blocks and PT
Description: Pain therapy utilizing Nerve Blocks with Physical Therapy
Study NCT01185795 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cardioviva™ yogurt
Description: L. reuteri cardioviva in yogurt, twice per day (BID), 6 weeks
Study NCT02038257 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vaseline Impregnated Gauze
Description: Each subject will have MKTP on 4 distinct areas of depigmented skin. Two of these areas will be dressed with vaseline impregnated gauze.
Study NCT03382639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luvadaxistat
Description: TAK-831 tablets.
Study NCT03382639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Luvadaxistat placebo-matching tablets.
Study NCT02038257 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carbon Dioxide Laser
Description: Each subject will have MKTP on 4 distinct areas of depigmented skin. Two of these areas will be de-epithelialized using a carbon dioxide laser.
Study NCT01528722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.25% 20ml administered intraperitoneal
Study NCT01528722 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normal saline
Description: sodium chloride 0.9% solution
Study NCT03739346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Therapeutic technique in which clinicians make suggestions to individuals who have undergone a procedure designed to relax them and focus their minds.
Study NCT03739346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tell, show, do technique
Description: The technique involves verbal explanations of procedures in phrases appropriate to the developmental level of the patient (tell); demonstrations for the patient of the visual, auditory, olfactory, and tactile aspects of the procedure in a carefully defined, nonthreatening setting (show); and then, without deviating from the explanation and demonstration, completion of the procedure (do). Tell-show-do technique is used with communication skills (verbal and nonverbal) and positive reinforcement.
Study NCT02133612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel; cisplatin
Description: The adjuvant chemotherapy regimen consisted of paclitaxel 150mg/m2 intravenously (IV) over 3 hours on day 1, followed by cisplatin 50mg/m2 IV on day 2 every 14 days for 4 to 6 cycles.
Study NCT02275156 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection
Study NCT03107494 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gala Airway Treatment System
Description: The Gala Airway Treatment system is a device-based, energy delivery system that delivers high frequency short duration energy to the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope. In this study, 2 treatment sessions will be delivered 1 month apart. The right lung is treated at the first treatment session and the left lung is treated at the second treatment session. A third bronchoscopy will be performed 3 months following the second treatment session where treatment is not delivered but a cryo-biopsy will be taken from the airway sites that have been treated during the two previous bronchoscopic treatment session to evaluate the effect of the treatment on the airways producing excessive mucous. Subjects will be required to submit to several tests during the study including two CT scans (lung), respiratory function tests, exercise testing.
Study NCT00002812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IV
Study NCT01708473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advil
Description: One (1) tablet 800 mg Advil one hour prior to treatment.
Study NCT01708473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lortab
Description: One (1) tablet 10/500 mg of Lortab one hour prior to treatment.
Study NCT00002812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT01708473 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin
Study NCT00002812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT00002812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV
Study NCT00002812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV
Study NCT00002812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00002812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV
Study NCT04081246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bipolar transurethral modified en bloc resection of bladder tumour
Description: Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)
Study NCT01072175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2118436
Description: GSK2118436 is a potent and selective inhibitor of BRAF kinase activity with a mode of action consistent with adenosine triphosphate-competitive inhibition.
Study NCT01072175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: GSK1120212 is a potent and highly selective inhibitor of MEK1/2 activation and kinase activity.
Study NCT00002812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given IV
Study NCT00002812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given PO
Study NCT00002812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Given IV
Study NCT00002812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO
Study NCT00002812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given IV
Study NCT02058849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beetroot
Description: 10g Beetroot powder mixed with 4-8 oz.
Study NCT00002812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT00002812 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT02058849 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02968095 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message Craving Program
Description: Text messages targeting cravings delivered 2-3 times per day.
Study NCT02968095 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Help Manual Plus Control Texts
Description: Self-help manual plus motivational text messages delivered 2-3 times per day.
Study NCT02083406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800mg OZ439 prototype formulation 1
Study NCT00293618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic Risk Presentation in the operating room
Description: Automatic calculation and presentation of a patient's individual predicted PONV risk by the anesthesia information management system during the entire procedure
Study NCT00293618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Specific information is provided to the intervention group: about PONV, about the prediction model. While the Usual Care group only receives information about the study purposes
Study NCT00293618 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Specific information is provided to the intervention group: about PONV, about the prediction model. While the Usual Care group only receives information about the study purposes
Study NCT00293618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feedback
Description: Feedback about the physician's personal performance on prevention of PONV
Study NCT03392818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The measured distance
Description: To measure the distance between the upper edge of the thyroid cartilage to the upper edge of the sternum add the distance from the upper edge of the sternum to the carina calculated according to the chest CT scans as a guide to the placement of Uniblocker without the aid of Fiberoptic bronchoscope.
Study NCT03392818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: formula
Description: Calculate the depth of intubation according to the formula of 0.1977\* patient's height - 4.2423
Study NCT03392818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fiberoptic bronchoscope
Description: The intubation of Uniblocker under the guidance of Fiberoptic bronchoscope
Study NCT03872856 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BP-ICAN
Description: One of two home blood pressure monitor devices will be used.~1. Omron 7 Series Wrist cuff~2. Omron 10 Series Upper Arm cuff
Study NCT02205242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: From day 1 up to and including day 3: 500 mg azithromycin or placebo PO once a day From day 4 up to and including day 90: 250 mg azithromycin or placebo PO once every 2 days
Study NCT02205242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynaport®
Description: Registering physical activity during 7 days post discharge from hospital (0 months), 3 months and 9 months
Study NCT02205242 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dynaport®
Description: Registering physical activity during 7 days post discharge from hospital (0 months), 3 months and 9 months
Study NCT02205242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04146935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Burosumab Injection [Crysvita]
Description: Burosumab/Crysvita SC injection monthly
Study NCT03207633 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive trans-magnetic stimulation (rTMS) on DLPFC
Description: Repetitive trans-magnetic stimulation (rTMS) on DLPFC